Evidence map›Paper›PMID 42180941›Full record

ArticleTranslational cancer research2026

Prognostic value and therapeutic implications of HMGA2 in EGFR-mutant non-small cell lung cancer.

Yichen Yang, Shixuan Yan, Zitao Liu, Zhibing Luo, Jie Wang, Ganxiu Deng, Jianjun Zhou, Li Xu, Changwen Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yichen Yang *Department of Cardiothoracic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
Shixuan Yan *Department of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, China.
Zitao Liu *Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Zhibing LuoDepartment of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, China.
Jie WangDepartment of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, China.
Ganxiu DengDepartment of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, China.
Jianjun Zhou *Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine, Shenzhen, China.
Li Xu *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Changwen Deng *Department of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: HMGA2, an oncoprotein associated with tumor progression and metastasis, is frequently overexpressed in various cancers. However, its specific role in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) remains unclear. This study aimed to investigate the prognostic significance of High mobility group AT-hook 2 (HMGA2), its relationship with EGFR mutations, and its impact on tumor microenvironment (TME) dynamics to identify potential therapeutic targets. Methods: The expression of Results: These results indicated that Conclusions: In conclusion, HMGA2 expression is positively correlated with the EGFR mutation status, suggesting its potential as a diagnostic and prognostic marker for LUAD.

Indexed as

epidermal growth factor receptor (EGFR)HMGA2non-small cell lung cancer (NSCLC)prognosistumor immunology

Identifiers

PMID42180941
PMCPMC13190963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.